Page last updated: 2024-11-11

4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo(1,5-a)pyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo(1,5-a)pyrimidine: an hCRF(1) antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9884878
CHEMBL ID45187
SCHEMBL ID13134050
MeSH IDM0375098

Synonyms (17)

Synonym
PDSP2_001281
PDSP1_001297
4-(3-pentylamino)-dmmpp
4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)pyrazolo(1,5-a)pyrimidine
dmp904
dmp-904
bdbm50087713
(1-ethyl-propyl)-[3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-amine
CHEMBL45187 ,
sp90--4
202579-74-6
SCHEMBL13134050
dmp 904
3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine
sp-904 pound>>dmp 904 pound>>dmp904
BCP26370
AMY15349

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"In conclusion, we have shown for the first time, an automated blood sampling technique that can be incorporated to identify pharmacodynamic biomarkers in-vivo."( Automated blood sampling to identify pharmacodynamics biomarkers of corticotrophin releasing factor receptor 1 antagonism.
Da Costa Mathews, C; Fish, R; Katugampola, SD; Wood, C; Young, K,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.01000.00070.06490.3400AID614443
Corticotropin-releasing factor receptor 1Homo sapiens (human)Ki0.00110.00080.01020.2400AID1428279; AID223380; AID614444; AID622045
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)Kd0.00030.00030.00030.0003AID622092
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1428280Clearance in Beagle dog at 5 mg/kg, iv administered as single dose by LC/MS/MS analysis2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID1428281Volume of distribution at steady state in Beagle dog at 5 mg/kg, iv administered as single dose by LC/MS/MS analysis2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID1428223Half life in Beagle dog at 5 mg/kg, iv administered as single dose by LC/MS/MS analysis2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID622092Binding affinity to recombinant human CRF1 receptor expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID227436Percent reduction in latency time in the dark compartment at 20 mg/kg was reported2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID225959Minimum effective dose in rat stimulantional anxiety test when administered perorally2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID622045Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as inhibition of CRF-induced cAMP formation2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID225453Oral activity was evaluated in an rat situational anxiety test2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID1428279Displacement of [125I-Tyr0]-CRF from recombinant human CRF1 receptor2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
AID614443Antagonist activity at human corticotropin-releasing factor receptor 1 expressed in CHO-K1 cells assessed as inhibition of CRF-induced cAMP production after 15 mins by enzyme immunoassay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
AID223380Compound was tested for the binding affinity to human corticotropin releasing factor 1 (hCRF1) receptors2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID622091Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as dissociation half life2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID614444Displacement of [125I]CRF from human corticotropin-releasing factor receptor 1 expressed in CHO-K1 cells after 2 hrs by gamma counting2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
AID622093Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as suppression on CRF1-induced maximum response by Schild analysis assay2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID82375Inhibition of h- CRF mediated increase in adenylate cyclase activity was evaluated in HEK293 cells2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID1428282Half life in Beagle dog at 5 mg/kg, po administered as single dose by LC/MS/MS analysis2017European journal of medicinal chemistry, Jan-27, Volume: 126An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (60.00)29.6817
2010's6 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (18.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (81.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]